Vertex Pharmaceuticals (NASDAQ: VRTX) furnishes Q3 2025 and YTD results press release

Rhea-AI Filing Summary

Vertex Pharmaceuticals Incorporated filed a current report to note that it has released its latest quarterly and year-to-date financial results. On November 3, 2025, the company issued a press release reporting consolidated financial results for the three and nine months ended September 30, 2025. That press release is furnished as Exhibit 99.1 to this report and is incorporated by reference, but is not treated as "filed" for liability purposes under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202025-11-032025-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 3, 2025

Vertex Pharmaceuticals Incorporated

(Exact name of registrant as specified in its charter)

Massachusetts			000-19319			04-3039129
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

50 Northern Avenue

Boston, Massachusetts 02210

(Address of principal executive offices) (Zip Code)

(617) 341-6100

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 Par Value Per Share

VRTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition.

On November 3, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

Exhibit						Description of Document
99.1						Press Release Dated November 3, 2025.
104						Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			VERTEX PHARMACEUTICALS INCORPORATED
			(Registrant)
Date: November 3, 2025			/s/ Jonathan Biller
			Jonathan Biller
			Executive Vice President, Chief Legal Officer

FAQ

What did Vertex Pharmaceuticals (VRTX) report in this 8-K?

Vertex Pharmaceuticals reported that it issued a press release with its consolidated financial results for the three and nine months ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which period do the Vertex (VRTX) results in this filing cover?

The press release referenced in this filing covers Vertex's consolidated financial results for the three and nine months ended September 30, 2025.

How did Vertex Pharmaceuticals provide its Q3 2025 financial results?

Vertex Pharmaceuticals provided its Q3 2025 and year-to-date financial results through a press release dated November 3, 2025, which is attached to the report as Exhibit 99.1.

Is the Vertex (VRTX) earnings press release considered 'filed' with the SEC?

No. The company states that the information in Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Where can investors find the detailed financial numbers for Vertex's Q3 2025?

The detailed financial numbers are contained in the press release dated November 3, 2025, which is attached as Exhibit 99.1 and incorporated by reference into the report.

Who signed this Vertex Pharmaceuticals (VRTX) 8-K?

The report was signed on behalf of Vertex Pharmaceuticals Incorporated by Jonathan Biller, Executive Vice President and Chief Legal Officer, on November 3, 2025.